BioVex, Inc. Lands $40,000,000 Series F Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ea819afd-0fdf-4a8c-8cad-e73ca7d6bb6a&Preview=1 -
Date
3/30/2009 -
Company Name
BioVex, Inc. -
Mailing Address
34 Commerce Way Woburn, MA 01801 -
Company Description
The Company is developing a new class of potent biologics for the treatment
of cancer and prevention of infectious disease. -
Website
http://www.biovex.com -
Transaction Type
Venture Equity -
Transaction Amount
$40,000,000 -
Transaction Round
Series F -
Proceeds Purposes
Following the unprecedented number of durable complete remissions generated with our lead cancer product, OncoVEX GM-CSF in a Phase II study in metastatic melanoma, the funds will be used to commence a pivotal Phase III study. -
M&A Terms
-
Venture Investor
Forbion Capital Partners (FKA ABN) -
Venture Investor
Harris & Harris Group -
Venture Investor
New Science Ventures -
Venture Investor
Triathlon Medical Ventures -
Venture Investor
Innoven Partners -
Venture Investor
SEP – Scottish Equity Partners
